Status:
TERMINATED
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
ImmunoGen, Inc.
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Detailed Description
Small-Cell Lung Cancer (SCLC) is a neuroendocrine cancer of the lung that is typically caused by smoking. Patients generally present with symptoms of cough, dyspnea, pain and weakness, and often have ...
Eligibility Criteria
Inclusion
- Patients must be 18 years old
- Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease
- ECOG performance status of 0, 1, or 2
- No prior systemic chemotherapy for the treatment of SCLC
Exclusion
- \- Pregnant or lactating females
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT01237678
Start Date
November 1 2010
End Date
May 1 2015
Last Update
January 18 2018
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Cancer Center @ UMC North
Tucson, Arizona, United States, 85719
2
UCLA Oncology Center
Los Angeles, California, United States, 90095
3
St. Joseph's Hospital
Orange, California, United States, 92868
4
UCLA Hematology
Pasadena, California, United States, 91105